Surveillance for Multisystem Inflammatory Syndrome in US Children Aged 5-11 Years Who Received Pfizer-BioNTech COVID-19 Vaccine, November 2021 through March 2022

J Infect Dis. 2023 Jul 14;228(2):143-148. doi: 10.1093/infdis/jiad051.


Multisystem inflammatory syndrome in children (MIS-C) is a complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; in the United States, reporting of MIS-C after coronavirus disease 2019 (COVID-19) vaccination is required for vaccine safety monitoring. Pfizer-BioNTech COVID-19 vaccine was authorized for children aged 5-11 years on 29 October 2021. Covering a period when approximately 7 million children received vaccine, surveillance for MIS-C ≤ 90 days postvaccination using passive systems identified 58 children with MIS-C and laboratory evidence of past/recent SARS-CoV-2 infection, and 4 without evidence. During a period with extensive SARS-CoV-2 circulation, MIS-C illness in children after COVID-19 vaccination who lacked evidence of SARS-CoV-2 infection was rare (<1 per million vaccinated children).

Keywords: COVID-19; COVID-19 vaccine; MIS-C; SARS-CoV-2; multisystem inflammatory syndrome in children.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • BNT162 Vaccine
  • COVID-19 Vaccines* / adverse effects
  • COVID-19* / prevention & control
  • Child
  • Humans
  • SARS-CoV-2


  • COVID-19 Vaccines
  • BNT162 Vaccine

Supplementary concepts

  • pediatric multisystem inflammatory disease, COVID-19 related